These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000506-52 Randomised Olmesartan and Diabetes Microalbuminuria prevention study 2009-06-02 due-trials
Reported results 2004-000696-34 A Phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of a plati... 2005-10-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-002437-39 A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan)Administered for 72 Hours by Continuous ... 2006-10-24 bad-data
Completed, but no date, and reported results 2004-003195-11 The effect of the co-administration of multiple oral doses of the fructose-1,6-bisphosphatase (FBPase) inhibitor CS-917 and glibenclamide on pharmacokinetics, safety and tolerability in diabetic patie... bad-data
Ongoing, reported early 2004-004415-29 A Phase IIa, multi-center, multi-national, open-label, dose ranging study of the efficacy, safety, and tolerability of oral DU-176b administered once or twice daily in the treatment of adult patients ... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-000447-28 EFFICACY AND SAFETY OF AMLODIPINE USED AS ADD-ON THERAPY IN MODERATELY TO SEVERELY HYPERTENSIVE PATIENTS NOT ADEQUATELY CONTROLLED BY OLMESARTAN MEDOXOMIL 20 MG MONOTHERAPY 2006-11-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000450-75 Add-on study of Olmesartan Medoximil in patients qith moderate to severe hypertension not achieving target blood pressure on Amlodipine 5mg alone. 2007-05-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003511-75 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients with Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins... 2007-12-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-004659-36 Treat-to-target study of olmesartan medoxomil and an add-on treatment algorithm consisting of hydrochlorothiazide and amlodipine besylate in patients with mild to moderate hypertension 2008-04-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-000758-29 A PHASE IIB, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE-DUMMY, MULTI-CENTER, MULTI NATIONAL, MULTI-DOSE STUDY OF DU-176b COMPARED TO DALTEPARIN IN PATIENTS UNDERGOING ELECTIVE UNILATERAL TOTAL H... 2007-06-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003876-37 Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy 2008-03-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003877-28 Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg versus 40/25 mg in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 4... 2008-05-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005047-28 A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS 2009-02-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001271-11 A PHASE 2, RANDOMIZED, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF SAFETY OF FOUR FIXED DOSE REGIMENS OF DU-176b IN SUBJECTS WITH NON-VALVULAR ATRIAL FIBRILLATION 2008-08-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-003060-22 A 24-week multicentre, randomised, double blind, controlled, parallel group non-inferiority study to assess the efficacy and safety of olmesartan medoxomil versus candesartan cilexetil in patients wit... 2009-08-12 bad-data
Reported results 2007-003130-41 Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients with Metabolic Syndrome 2010-12-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-003131-23 Effect of olmesartan medoxomil on arterial stiffness and thickness in subjects with metabolic syndrome 2011-08-08 bad-data
Completed, but no date, and reported results 2007-004574-11 RANDOMISED, DOUBLE-BLINDED, PLACEBO- CONTROLLED PHASE 2 STUDY OF CS-1008 IN COMBINATION WITH CARBOPLATIN/PACLITAXEL IN CHEMOTHERAPY NAÏVE SUBJECTS WITH METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG ... bad-data
Reported results 2007-005263-97 A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS 2008-04-23 due-trials
Reported results 2007-005675-34 A PHASE 2 OPEN-LABEL RANDOMISED, TRIAL OF CS-1008 IN COMBINATION WITH IRINOTECAN VS IRINOTECAN ALONE IN SUBJECTS WITH METASTATIC COLORECTAL CARCINOMA WHO FAILED FIRST LINE OXALIPLATIN BASED CHEMOTHERA... 2011-05-30 due-trials
Reported results 2008-003534-25 A randomised, double-blind, parallel group study evaluating the efficacy and safety of co administration of triple combinations of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide co... 2011-01-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-003535-20 A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE COMBI... 2010-09-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004522-16 A Phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillat... 2013-06-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005848-16 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 2 STUDY OF CS 7017 IN COLORECTAL CANCER PATIENTS WHO HAVE ACHIEVED DISEASE CONTROL FOLLOWING FIRST-LINE CHEMOTHERAPY 2012-05-31 bad-data
Ongoing, reported early 2009-012966-30 “Eficacia de Sevikar® comparado con la combinación de Perindoprilo/Amlodipino sobre la Presión Arterial Central, en Pacientes con Hipertensión moderada a severa - SEVITENSION” not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-013342-92 Effects of angiotensin-receptor blockade with olmesartan on carotid atherosclerosis in patients with hypertension: the CONFIRMatory olmesartan plaque regression study (CONFIRM) 2011-09-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-014290-40 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP,MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS (LMW) 2013-04-30 bad-data
Ongoing, reported early 2009-015400-26 MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS not-yet-due
Reported results 2009-016025-34 A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 1/2 STUDY OF ARQ 197 IN COMBINATION WITH IRINOTECAN AND CETUXIMAB IN SUBJECTS WITH METASTATIC COLORECTAL CANCER WITH WILD-TYPE KRAS WHO HAVE RECEIVED FRONT-LINE... 2014-12-16 due-trials
Reported results 2009-016083-36 Phase 2 Study of CS-7017 and Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy 2013-04-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-021082-74 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO H... 2013-12-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-022365-10 A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous... 2016-10-06 bad-data
Reported results 2011-004064-29 A PHARMACODYNAMIC EVALUATION OF SWITCHING FROM TICAGRELOR TO PRASUGREL IN SUBJECTS WITH STABLE CORONARY ARTERY DISEASE: 2ND SWITCHING ANTIPLATELET AGENTS (SWAP 2) 2013-02-13 due-trials
Reported results 2012-003009-88 A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, 2014-12-03 due-trials
Reported results 2012-003308-10 A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197) IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY 2017-03-02 due-trials
Reported results 2012-004373-80 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord ... 2015-03-21 due-trials
Reported results 2013-000104-42 Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension 2014-04-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-003148-21 A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing ... 2016-02-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-004371-12 Phase 3, Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wild-type Subjects with Locally Advanced or Metastatic... 2016-05-18 bad-data
Ongoing 2013-004890-28 A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After Fir... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-005161-40 A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia 2016-07-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-005162-20 A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia 2017-01-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-005163-10 A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia 2016-07-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-005164-26 An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia 2017-04-19 bad-data
Other 2014-000148-14 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN not-yet-due
Completed, reported early 2014-003972-21 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SAFETY STUDY OF DS-5565 FOR TREATMENT OF PAIN DUE TO FIBROMYALGIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE 2017-07-06 not-yet-due
Completed, report not yet due 2014-004708-30 A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH ... 2017-09-15 not-yet-due
Ongoing 2015-001824-43 A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, phar... not-yet-due
Listed as ongoing, but also has a completion date 2015-002222-40 Randomized, Placebo-Controlled, Double Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum Based Therapy in First Line Setting in Subjects with Recurrent or Metasta... 2018-02-21 bad-data
No trial status on register 2015-003005-41 A Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of a Compounded 4 mg/mL Olmesartan Medoxomil Suspension (Total Dose 40 mg) and 40 mg Olmesartan Medoxomil Tablets (Benicar... bad-data
No trial status on register 2015-003328-30 An Open-Label Study of the Single-Dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension bad-data
No trial status on register 2015-003329-32 Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension bad-data
Ongoing 2015-004856-24 A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects ... not-yet-due
Ongoing 2015-005211-32 A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to Sta... not-yet-due
Ongoing 2015-005732-18 A Phase 1, Open-Label, Single-dose, Non-randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients not-yet-due
Ongoing 2016-000979-24 Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after st... not-yet-due
Other 2016-000991-49 A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTI-CENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF ... not-yet-due
Ongoing 2016-001795-30 Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance not-yet-due
Ongoing 2016-002683-14 Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent plac... not-yet-due
Other 2016-002919-18 A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and ... not-yet-due
Ongoing 2016-003069-25 A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation ... not-yet-due
Ongoing 2016-003930-26 Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation – In Atrial Fibrillation. not-yet-due
Ongoing 2016-004986-18 A Phase 2, Multicenter, Open-Label Study of DS-8201a, an not-yet-due
Ongoing 2017-000475-90 AN OPEN-LABEL, RANDOMISED, PARALLEL-GROUP, MULTICENTRE, OBSERVATIONAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF EDOXABAN TOSYLATE IN CHILDREN FROM 38 WEEKS GESTATIONAL AGE TO LESS THAN 18 YEARS OF AGE ... not-yet-due
Completed, but no date 2017-000552-25 Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE) bad-data
Ongoing 2017-003466-28 A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer not-yet-due